168 related articles for article (PubMed ID: 32505524)
1. Eligibility of CFTR modulators for the adult-diagnosed cystic fibrosis population.
Desai S; Lam GY; Sykes J; Stephenson AL; Quon BS
J Cyst Fibros; 2020 Sep; 19(5):840-841. PubMed ID: 32505524
[No Abstract] [Full Text] [Related]
2. CFTR modulator use in post lung transplant recipients.
Benninger LA; Trillo C; Lascano J
J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
[No Abstract] [Full Text] [Related]
4. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
Terlizzi V
J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
[No Abstract] [Full Text] [Related]
5. CFTR modulators: transformative therapies for cystic fibrosis.
Dwight M; Marshall B
J Manag Care Spec Pharm; 2021 Feb; 27(2):281-284. PubMed ID: 33506726
[No Abstract] [Full Text] [Related]
6. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
7. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
8. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
[No Abstract] [Full Text] [Related]
9. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
Fortner CN; Seguin JM; Kay DM
J Cyst Fibros; 2021 Sep; 20(5):835-836. PubMed ID: 33846105
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
Hong E; Zampoli M; Beringer PM
Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
[No Abstract] [Full Text] [Related]
11. Unmasking catamenial hemoptysis in the era of CFTR modulator therapy.
Montemayor K; Claudio AT; Carson S; Lechtzin N; Christianson MS; West NE
J Cyst Fibros; 2020 Jul; 19(4):e25-e27. PubMed ID: 31987762
[TBL] [Abstract][Full Text] [Related]
12. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
13. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
14. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease.
B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G
J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524
[No Abstract] [Full Text] [Related]
15. Year in review 2023 - Back to the future.
Cristiani L; Fernandes FF
J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442
[TBL] [Abstract][Full Text] [Related]
16. To treat or not to treat: CFTR modulators after lung transplantation.
Hayes D; Darland LK; Hjelm MA; Mansour HM; Wikenheiser-Brokamp KA
Pediatr Transplant; 2021 Jun; 25(4):e14007. PubMed ID: 33742748
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More
Griese M; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Taylor-Cousar JL; Withers NJ; Moskowitz SM; Daines CL
Am J Respir Crit Care Med; 2021 Feb; 203(3):381-385. PubMed ID: 32969708
[No Abstract] [Full Text] [Related]
18. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
[TBL] [Abstract][Full Text] [Related]
19. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
20. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
Chun SW; Somers ME; Burgener EB
Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
